• Something wrong with this record ?

Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen

C. Stergiou, K. Lazaridis, V. Zouvelou, J. Tzartos, R. Mantegazza, C. Antozzi, F. Andreetta, A. Evoli, F. Deymeer, G. Saruhan-Direskeneli, H. Durmus, T. Brenner, A. Vaknin, S. Berrih-Aknin, A. Behin, T. Sharshar, M. De Baets, M. Losen, P....

. 2016 ; 292 (-) : 108-15. [pub] 20160127

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16027609

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies targeting the neuromuscular junction of skeletal muscles. Triple-seronegative MG (tSN-MG, without detectable AChR, MuSK and LRP4 antibodies), which accounts for ~10% of MG patients, presents a serious gap in MG diagnosis and complicates differential diagnosis of similar disorders. Several AChR antibody positive patients (AChR-MG) also have antibodies against titin, usually detected by ELISA. We have developed a very sensitive radioimmunoprecipitation assay (RIPA) for titin antibodies, by which many previously negative samples were found positive, including several from tSN-MG patients. The validity of the RIPA results was confirmed by western blots. Using this RIPA we screened 667 MG sera from 13 countries; as expected, AChR-MG patients had the highest frequency of titin antibodies (40.9%), while MuSK-MG and LRP4-MG patients were positive in 14.6% and 16.4% respectively. Most importantly, 13.4% (50/372) of the tSN-MG patients were also titin antibody positive. None of the 121 healthy controls or the 90 myopathy patients, and only 3.6% (7/193) of other neurological disease patients were positive. We thus propose that the present titin antibody RIPA is a useful tool for serological MG diagnosis of tSN patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027609
003      
CZ-PrNML
005      
20161025105159.0
007      
ta
008      
161005s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jneuroim.2016.01.018 $2 doi
024    7_
$a 10.1016/j.jneuroim.2016.01.018 $2 doi
035    __
$a (PubMed)26943968
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Stergiou, C $u Hellenic Pasteur Institute, Athens, Greece; Tzartos NeuroDiagnostics, Athens, Greece.
245    10
$a Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen / $c C. Stergiou, K. Lazaridis, V. Zouvelou, J. Tzartos, R. Mantegazza, C. Antozzi, F. Andreetta, A. Evoli, F. Deymeer, G. Saruhan-Direskeneli, H. Durmus, T. Brenner, A. Vaknin, S. Berrih-Aknin, A. Behin, T. Sharshar, M. De Baets, M. Losen, P. Martinez-Martinez, KA. Kleopa, E. Zamba-Papanicolaou, T. Kyriakides, A. Kostera-Pruszczyk, P. Szczudlik, B. Szyluk, D. Lavrnic, I. Basta, S. Peric, C. Tallaksen, A. Maniaol, NE. Gilhus, C. Casasnovas Pons, J. Pitha, M. Jakubíkova, F. Hanisch, J. Bogomolovas, D. Labeit, S. Labeit, SJ. Tzartos,
520    9_
$a Myasthenia gravis (MG) is an autoimmune disease caused by antibodies targeting the neuromuscular junction of skeletal muscles. Triple-seronegative MG (tSN-MG, without detectable AChR, MuSK and LRP4 antibodies), which accounts for ~10% of MG patients, presents a serious gap in MG diagnosis and complicates differential diagnosis of similar disorders. Several AChR antibody positive patients (AChR-MG) also have antibodies against titin, usually detected by ELISA. We have developed a very sensitive radioimmunoprecipitation assay (RIPA) for titin antibodies, by which many previously negative samples were found positive, including several from tSN-MG patients. The validity of the RIPA results was confirmed by western blots. Using this RIPA we screened 667 MG sera from 13 countries; as expected, AChR-MG patients had the highest frequency of titin antibodies (40.9%), while MuSK-MG and LRP4-MG patients were positive in 14.6% and 16.4% respectively. Most importantly, 13.4% (50/372) of the tSN-MG patients were also titin antibody positive. None of the 121 healthy controls or the 90 myopathy patients, and only 3.6% (7/193) of other neurological disease patients were positive. We thus propose that the present titin antibody RIPA is a useful tool for serological MG diagnosis of tSN patients.
650    _2
$a autoprotilátky $x krev $7 D001323
650    _2
$a konektin $x imunologie $7 D064211
650    _2
$a ELISA $7 D004797
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mezinárodní spolupráce $7 D007391
650    _2
$a proteiny související s LDL-receptory $x imunologie $7 D026502
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myasthenia gravis $x krev $x diagnóza $x epidemiologie $7 D009157
650    _2
$a radioimunoprecipitační analýza $7 D015531
650    _2
$a tyrosinkinasové receptory $x imunologie $7 D020794
650    _2
$a receptory cholinergní $x imunologie $7 D011950
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lazaridis, K $u Hellenic Pasteur Institute, Athens, Greece.
700    1_
$a Zouvelou, V $u Neurology Department, Aeginition Hospital, Athens, Greece.
700    1_
$a Tzartos, J $u Hellenic Pasteur Institute, Athens, Greece; Tzartos NeuroDiagnostics, Athens, Greece.
700    1_
$a Mantegazza, R $u Neurological Institute "C. Besta", Milano, Italy.
700    1_
$a Antozzi, C $u Neurological Institute "C. Besta", Milano, Italy. $7 gn_A_00007581
700    1_
$a Andreetta, F $u Neurological Institute "C. Besta", Milano, Italy. $7 gn_A_00006435
700    1_
$a Evoli, A $u Institute of Neurology, Catholic University, Rome, Italy.
700    1_
$a Deymeer, F $u Istanbul University, Istanbul, Turkey.
700    1_
$a Saruhan-Direskeneli, G $u Istanbul University, Istanbul, Turkey.
700    1_
$a Durmus, H $u Istanbul University, Istanbul, Turkey.
700    1_
$a Brenner, T $u Hadassah Hebrew University Medical Center, Jerusalem, Israel.
700    1_
$a Vaknin, A $u Hadassah Hebrew University Medical Center, Jerusalem, Israel.
700    1_
$a Berrih-Aknin, S $u UPMC and INSERM, Paris, France.
700    1_
$a Behin, A $u UPMC and INSERM, Paris, France.
700    1_
$a Sharshar, T $u Raymond Poincaré Hospital, Garches, France.
700    1_
$a De Baets, M $u School for Mental Health and Neuroscience, Maastricht University, The Netherlands.
700    1_
$a Losen, M $u School for Mental Health and Neuroscience, Maastricht University, The Netherlands.
700    1_
$a Martinez-Martinez, P $u School for Mental Health and Neuroscience, Maastricht University, The Netherlands.
700    1_
$a Kleopa, K A $u The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
700    1_
$a Zamba-Papanicolaou, E $u The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
700    1_
$a Kyriakides, T $u The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
700    1_
$a Kostera-Pruszczyk, A $u Department of Neurology, Medical University of Warsaw, Poland.
700    1_
$a Szczudlik, P $u Department of Neurology, Medical University of Warsaw, Poland.
700    1_
$a Szyluk, B $u Department of Neurology, Medical University of Warsaw, Poland.
700    1_
$a Lavrnic, D $u Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia.
700    1_
$a Basta, I $u Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia.
700    1_
$a Peric, S $u Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia.
700    1_
$a Tallaksen, C $u Norway Department of Neurology, Ullevaal University Hospital, Oslo, Norway; Faculty of Medicine, Olso University, Norway.
700    1_
$a Maniaol, A $u Norway Department of Neurology, Ullevaal University Hospital, Oslo, Norway.
700    1_
$a Gilhus, N E $u Department of Clinical Medicine, University of Bergen, Norway.
700    1_
$a Casasnovas Pons, C $u Bellvitge University Hospital, Barcelona, Spain.
700    1_
$a Pitha, J $u Department of Neurology and Clinical Neuroscience Center, 1st Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic.
700    1_
$a Jakubíkova, M $u Department of Neurology and Clinical Neuroscience Center, 1st Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic.
700    1_
$a Hanisch, F $u Universitätsklinikum Halle, Halle, Germany.
700    1_
$a Bogomolovas, J $u Faculty of Clinical Medicine Manheim, University of Heidelberg, Germany.
700    1_
$a Labeit, D $u Faculty of Clinical Medicine Manheim, University of Heidelberg, Germany; Myomedix GmbH, 69151 Neckargemuend, Germany.
700    1_
$a Labeit, S $u Faculty of Clinical Medicine Manheim, University of Heidelberg, Germany.
700    1_
$a Tzartos, S J $u Hellenic Pasteur Institute, Athens, Greece; Tzartos NeuroDiagnostics, Athens, Greece. Electronic address: stzartos@gmail.com.
773    0_
$w MED00002834 $t Journal of neuroimmunology $x 1872-8421 $g Roč. 292, č. - (2016), s. 108-15
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26943968 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161025105613 $b ABA008
999    __
$a ok $b bmc $g 1165923 $s 952239
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 292 $c - $d 108-15 $e 20160127 $i 1872-8421 $m Journal of neuroimmunology $n J Neuroimmunol $x MED00002834
LZP    __
$a Pubmed-20161005

Find record

Citation metrics

Archiving options